Cargando…

Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer

BACKGROUND: To aid clinicians strategizing treatment for upper esophageal squamous cell carcinoma (ESCC), this retrospective study investigated associations between primary gross tumor volume (GTVp) and prognosis in patients given surgical resection, radiotherapy, or both resection and radiotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuanmei, Huang, Qiuyuan, Chen, Junqiang, Lin, Yu, Huang, Xinyi, Wang, Qifeng, Yang, Yong, Chen, Bijuan, Ye, Yuling, Zheng, Binglin, Qi, Rong, Chen, Yushan, Xu, Yuanji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529770/
https://www.ncbi.nlm.nih.gov/pubmed/34670513
http://dx.doi.org/10.1186/s12885-021-08838-w
_version_ 1784586536303460352
author Chen, Yuanmei
Huang, Qiuyuan
Chen, Junqiang
Lin, Yu
Huang, Xinyi
Wang, Qifeng
Yang, Yong
Chen, Bijuan
Ye, Yuling
Zheng, Binglin
Qi, Rong
Chen, Yushan
Xu, Yuanji
author_facet Chen, Yuanmei
Huang, Qiuyuan
Chen, Junqiang
Lin, Yu
Huang, Xinyi
Wang, Qifeng
Yang, Yong
Chen, Bijuan
Ye, Yuling
Zheng, Binglin
Qi, Rong
Chen, Yushan
Xu, Yuanji
author_sort Chen, Yuanmei
collection PubMed
description BACKGROUND: To aid clinicians strategizing treatment for upper esophageal squamous cell carcinoma (ESCC), this retrospective study investigated associations between primary gross tumor volume (GTVp) and prognosis in patients given surgical resection, radiotherapy, or both resection and radiotherapy. METHODS: The population comprised 568 patients with upper ESCC given definitive treatment, including 238, 216, and 114 who underwent surgery, radiotherapy, or combined radiotherapy and surgery. GTVp as a continuous variable was entered into the multivariate Cox model using penalized splines (P-splines) to determine the optimal cutoff value. Propensity score matching (PSM) was used to adjust imbalanced characteristics among the treatment groups. RESULTS: P-spline regression revealed a dependence of patient outcomes on GTVp, with 30 cm(3) being an optimal cut-off for differences in overall and progression-free survival (OS, PFS). GTVp ≥30 cm(3) was a negative independent prognostic factor for OS and PFS. PSM analyses confirmed the prognostic value of GTVp. For GTVp < 30 cm(3), no significant survival differences were observed among the 3 treatments. For GTVp ≥30 cm(3), the worst 5-year OS rate was experienced by those given surgery. The 5-year PFS rate of patients given combined radiotherapy and surgery was significantly better than that of patients given radiotherapy. The surgical complications of patients given the combined treatment were comparable to those who received surgery, but radiation side effects were significantly lower. CONCLUSION: GTVp is prognostic for OS and PFS in upper ESCC. For patients with GTVp ≥30 cm(3), radiotherapy plus surgery was more effective than either treatment alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08838-w.
format Online
Article
Text
id pubmed-8529770
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85297702021-10-25 Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer Chen, Yuanmei Huang, Qiuyuan Chen, Junqiang Lin, Yu Huang, Xinyi Wang, Qifeng Yang, Yong Chen, Bijuan Ye, Yuling Zheng, Binglin Qi, Rong Chen, Yushan Xu, Yuanji BMC Cancer Research BACKGROUND: To aid clinicians strategizing treatment for upper esophageal squamous cell carcinoma (ESCC), this retrospective study investigated associations between primary gross tumor volume (GTVp) and prognosis in patients given surgical resection, radiotherapy, or both resection and radiotherapy. METHODS: The population comprised 568 patients with upper ESCC given definitive treatment, including 238, 216, and 114 who underwent surgery, radiotherapy, or combined radiotherapy and surgery. GTVp as a continuous variable was entered into the multivariate Cox model using penalized splines (P-splines) to determine the optimal cutoff value. Propensity score matching (PSM) was used to adjust imbalanced characteristics among the treatment groups. RESULTS: P-spline regression revealed a dependence of patient outcomes on GTVp, with 30 cm(3) being an optimal cut-off for differences in overall and progression-free survival (OS, PFS). GTVp ≥30 cm(3) was a negative independent prognostic factor for OS and PFS. PSM analyses confirmed the prognostic value of GTVp. For GTVp < 30 cm(3), no significant survival differences were observed among the 3 treatments. For GTVp ≥30 cm(3), the worst 5-year OS rate was experienced by those given surgery. The 5-year PFS rate of patients given combined radiotherapy and surgery was significantly better than that of patients given radiotherapy. The surgical complications of patients given the combined treatment were comparable to those who received surgery, but radiation side effects were significantly lower. CONCLUSION: GTVp is prognostic for OS and PFS in upper ESCC. For patients with GTVp ≥30 cm(3), radiotherapy plus surgery was more effective than either treatment alone. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08838-w. BioMed Central 2021-10-21 /pmc/articles/PMC8529770/ /pubmed/34670513 http://dx.doi.org/10.1186/s12885-021-08838-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Yuanmei
Huang, Qiuyuan
Chen, Junqiang
Lin, Yu
Huang, Xinyi
Wang, Qifeng
Yang, Yong
Chen, Bijuan
Ye, Yuling
Zheng, Binglin
Qi, Rong
Chen, Yushan
Xu, Yuanji
Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title_full Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title_fullStr Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title_full_unstemmed Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title_short Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
title_sort primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529770/
https://www.ncbi.nlm.nih.gov/pubmed/34670513
http://dx.doi.org/10.1186/s12885-021-08838-w
work_keys_str_mv AT chenyuanmei primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT huangqiuyuan primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT chenjunqiang primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT linyu primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT huangxinyi primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT wangqifeng primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT yangyong primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT chenbijuan primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT yeyuling primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT zhengbinglin primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT qirong primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT chenyushan primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer
AT xuyuanji primarygrosstumorvolumeisprognosticandsuggeststreatmentinupperesophagealcancer